Literature DB >> 21760505

Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification.

A Traverse-Glehen1, L Baseggio, G Salles, P Felman, F Berger.   

Abstract

PURPOSE OF REVIEW: Indolent B-cell lymphomas that are supposed to derive from marginal zone encompass three distinct entities: extranodal marginal zone lymphoma (MZL) or mucosa-associated lymphatic tissue (MALT), nodal MZL (NMZL) and splenic MZL (SMZL). Although MALT lymphoma is well characterized and extensively studied at the clinical and molecular levels, SMZL and NMZL remain incompletely characterized. However, during the last years, the clinical and molecular heterogeneity of SMZL has been clarified. The recent 2008 WHO classification has maintained the distinction between the three diseases according to the organ where it arises and introduced a new provisional category of unclassified splenic lymphoma for overlapping entities, splenic diffuse red pulp lymphoma (SDRPL) and hairy cell leukemia-variant (HCL-V). RECENT
FINDINGS: Recent findings in SMZL contributed to a better characterization, including the few cases associated with hepatitis C, the recurrence of 7q deletion and the possibility of CD5 expression. Furthermore, the peculiar pattern of immunoglobulin heavy chain genes mutations and the biased usage of immunoglobulin heavy chain variable region genes (IGHV)1-2 segment are suggestive of a T-independent antigen driven proliferation, at least at initial steps. This review will focus on recent findings and differential diagnosis with SDRPL and HCL-V.
SUMMARY: The conjunction of morphologic, cytogenetic and clinical data has increased diagnosis reproducibility.

Entities:  

Mesh:

Year:  2011        PMID: 21760505     DOI: 10.1097/CCO.0b013e328349ab8d

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  11 in total

1.  Splenic marginal zone lymphoma masquerading as cirrhotic hypersplenism for seven years.

Authors:  John Alfred Carr
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

2.  A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders.

Authors:  Gabriel Brisou; Aurélie Verney; Thomas Wenner; Lucile Baseggio; Pascale Felman; Evelyne Callet-Bauchu; Bertrand Coiffier; Françoise Berger; Gilles Salles; Alexandra Traverse-Glehen
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

3.  Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site.

Authors:  Mohammad O Khalil; Lindsay M Morton; Susan S Devesa; David P Check; Rochelle E Curtis; Dennis D Weisenburger; Graça M Dores
Journal:  Br J Haematol       Date:  2014-01-12       Impact factor: 6.998

4.  Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas.

Authors:  Monica Gostissa; Julia M Bianco; Daniel J Malkin; Jeffery L Kutok; Scott J Rodig; Herbert C Morse; Craig H Bassing; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

5.  Splenic marginal zone lymphoma in a HIV-1 infected patient: evidence favouring a pathogenetic role of HIV-1 itself in the lymphomagenesis.

Authors:  M Cagliuso; V Conti; S Trasarti; L Lombardi; M Riminucci; M Perez; O Turriziani; F Falasca; M Nanni; A Tafuri; I Mezzaroma
Journal:  Infection       Date:  2012-09-25       Impact factor: 3.553

6.  The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.

Authors:  Davide Rossi; Vladimir Trifonov; Marco Fangazio; Alessio Bruscaggin; Silvia Rasi; Valeria Spina; Sara Monti; Tiziana Vaisitti; Francesca Arruga; Rosella Famà; Carmela Ciardullo; Mariangela Greco; Stefania Cresta; Daniela Piranda; Antony Holmes; Giulia Fabbri; Monica Messina; Andrea Rinaldi; Jiguang Wang; Claudio Agostinelli; Pier Paolo Piccaluga; Marco Lucioni; Fabrizio Tabbò; Roberto Serra; Silvia Franceschetti; Clara Deambrogi; Giulia Daniele; Valter Gattei; Roberto Marasca; Fabio Facchetti; Luca Arcaini; Giorgio Inghirami; Francesco Bertoni; Stefano A Pileri; Silvia Deaglio; Robin Foà; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Gianluca Gaidano
Journal:  J Exp Med       Date:  2012-08-13       Impact factor: 14.307

7.  Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.

Authors:  Laurent Jallades; Lucile Baseggio; Pierre Sujobert; Sarah Huet; Kaddour Chabane; Evelyne Callet-Bauchu; Aurélie Verney; Sandrine Hayette; Jean-Pierre Desvignes; David Salgado; Nicolas Levy; Christophe Béroud; Pascale Felman; Françoise Berger; Jean-Pierre Magaud; Laurent Genestier; Gilles Salles; Alexandra Traverse-Glehen
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

8.  Unusual Course of Splenic Marginal Zone Lymphoma.

Authors:  Nay T Tun; Kaihong Mi; John Smith
Journal:  World J Oncol       Date:  2013-09-27

9.  Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges.

Authors:  Tayse Silva Dos Santos; Renato Sampaio Tavares; Danielle Leão Cordeiro de Farias
Journal:  Rev Bras Hematol Hemoter       Date:  2016-12-22

10.  Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Authors:  Eloy F Robles; Maria Mena-Varas; Laura Barrio; Sara V Merino-Cortes; Péter Balogh; Ming-Qing Du; Takashi Akasaka; Anton Parker; Sergio Roa; Carlos Panizo; Idoia Martin-Guerrero; Reiner Siebert; Victor Segura; Xabier Agirre; Laura Macri-Pellizeri; Beatriz Aldaz; Amaia Vilas-Zornoza; Shaowei Zhang; Sarah Moody; Maria Jose Calasanz; Thomas Tousseyn; Cyril Broccardo; Pierre Brousset; Elena Campos-Sanchez; Cesar Cobaleda; Isidro Sanchez-Garcia; Jose Luis Fernandez-Luna; Ricardo Garcia-Muñoz; Esther Pena; Beatriz Bellosillo; Antonio Salar; Maria Joao Baptista; Jesús Maria Hernandez-Rivas; Marcos Gonzalez; Maria Jose Terol; Joan Climent; Antonio Ferrandez; Xavier Sagaert; Ari M Melnick; Felipe Prosper; David G Oscier; Yolanda R Carrasco; Martin J S Dyer; Jose A Martinez-Climent
Journal:  Nat Commun       Date:  2016-06-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.